Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
NCT06607692
Adrenal Cortex Diseases, Adrenal Cortex Neoplasms
Boadilla del Monte, Madrid, Spain
View Trial Details